UTILIZING PREDICTIVE BIOMARKERS TO IMPROVE TREATMENT OUTCOMES IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): RESULTS WITH CETUXIMAB PLUS FOLFIRI IN THE CRYSTAL TRIAL

被引：0
|
作者：
Rougier, P. [1 ]
Janciauskiene, R. [2 ]
Paramonov, V [3 ]
Shparyk, Y. [4 ]
Gustavsson, B. [5 ]
Wagnerova, M. [6 ]
Gorbunova, V [7 ]
Utracka-Hutka, B. [8 ]
Celik, I [9 ]
Van Cutsem, E. [10 ]
机构：
[1] Hop Ambroise Pare, Boulogne, France
[2] Kauno Med Univ Klin, Kaunas, Lithuania
[3] Cherkassy Oblasnoy Onkodispanser, Charkassy, Ukraine
[4] Lviv Oncol Med & Diagnost Ctr, Lvov, Ukraine
[5] Sahlgrens Univ Hosp, Gothenburg, Sweden
[6] Vychodoslovensky Onkol Ustav, Kosice, Slovakia
[7] RAMN, NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[8] MSC Mem Canc Ctr, Gliwice, Poland
[9] Merck KGaA, Darmstadt, Germany
[10] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [1] Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial
    Kohne, C.
    Stroiakovski, D.
    Chang-Chien, C.
    Lim, R.
    Pinter, T.
    Bodoky, G.
    Stroh, C.
    Celik, I.
    Rougier, P.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] IMPACT ON QUALITY OF LIFE OF CETUXIMAB PLUS FOLFIRI IN THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): RESULTS FROM THE CRYSTAL TRIAL
    Lang, I
    Aleknaviciene, B.
    Zolotukhin, S.
    Komissarenko, V
    Garcia-Alfonso, P.
    Jurga, L.
    Moiseyenko, V
    Filipczyk-Cisarz, E.
    Zubel, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2009, 20 : 23 - 24
  • [3] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [4] Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial
    Ciardiello, Fortunato
    Lenz, Heinz-Josef
    Kohne, Claus-Henning
    Heinemann, Volker
    Tejpar, Sabine
    Esser, Regina
    Beier, Frank
    Stroh, Christopher
    Duecker, Klaus
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)
    Van Cutsem, E.
    Bodoky, G.
    Kyung Roh, J.
    Folprecht, G.
    Park, Y. S.
    Van Laethem, J. L.
    Raoul, J. L.
    Ciardiello, F.
    Lebrun, P.
    Rougier, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 235 - 235
  • [6] Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial
    Folprecht, G.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Zubel, A.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Liver and/or lung metastasectomy after cetuximab or bevacizumab plus FOLFIRI chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC).
    Kim, Sang-A
    Kim, Ji-Won
    Suh, Koung Jin
    Kim, Jin Won
    Oh, Heung-Kwon
    Cho, Jai Young
    Kim, Duck-Woo
    Lee, Keun-Wook
    Cho, Sukki
    Kim, Jee Hyun
    Kim, Kwhanmien
    Kang, Sung-Bum
    Jheon, Sanghoon
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [8] Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
    Ocvirk, Janja
    Brodowicz, Thomas
    Wrba, Fritz
    Ciuleanu, Tudor E.
    Kurteva, Galina
    Beslija, Semir
    Koza, Ivan
    Zsuzsanna Papai
    Messinger, Diethelm
    Yilmaz, Ugur
    Zsolt Faluhelyi
    Yalcin, Suayib
    Papamichael, Demetris
    Miklos Wenczl
    Mrsic-Krmpotic, Zrinka
    Shacham-Shmueli, Einat
    Vrbanec, Damir
    Esser, Regina
    Scheithauer, Werner
    Zielinski, Christoph C.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (25) : 3133 - 3143
  • [9] Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
    Janja Ocvirk
    Thomas Brodowicz
    Fritz Wrba
    Tudor E Ciuleanu
    Galina Kurteva
    Semir Beslija
    Ivan Koza
    Zsuzsanna Pápai
    Diethelm Messinger
    Ugur Yilmaz
    Zsolt Faluhelyi
    Suayib Yalcin
    Demetris Papamichael
    Miklós Wenczl
    Zrinka Mrsic-Krmpotic
    Einat Shacham-Shmueli
    Damir Vrbanec
    Regina Esser
    Werner Scheithauer
    Christoph C Zie-linski
    World Journal of Gastroenterology, 2010, 16 (25) : 3133 - 3143
  • [10] KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
    Van Cutsem, E.
    Lang, I.
    D'haens, G.
    Moiseyenko, V.
    Zaluski, J.
    Folprecht, G.
    Tejpar, S.
    Kisker, O.
    Stroh, C.
    Rougier, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345